NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.에 대해 보유한 최신 분기

기업이 직접 제출한 6-K에서 가져왔습니다.

경영진의 발언

“Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

NeuroSense Therapeutics Ltd.은(는) 무엇을 하는 기업인가

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within approximately 3 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

발표 자료 말미에 실린 기업 자신의 소개글입니다.